Table 2.

Characteristics of the included studies.

Included study	Sample size (T/C)	Treatment		Gender (M/F)		Age (years)		Treatment course (days)	Random method	Evaluation indicators
		Experimental group	Control group	Experimental group	Control group	Experimental group	Control group
Yang Xi, 2020 [9]	20/29	Xueshuantong injection + low molecular weight heparin	Low molecular weight heparin	0/20	0/29	56.45 ± 19.74	57.05 ± 21.74	14	Random number table	7；8；9
Lan Jinyao, 2019 [10]	91/91	Xueshuantong injection + low molecular weight heparin	Low molecular weight heparin	50/41	42/49	51.72 ± 16.82	48.73 ± 18.27	14	Random number table	1；7；9
Pei Guanghua, 2019 [11]	36/36	Xueshuantong injection + urokinase injection	Urokinase injection	20/16	21/15	62.9 ± 1.1	62.8 ± 1.2	14	Random number table	1；2；3；4
Shi Yiwen, 2019 [12]	38/38	Xueshuantong injection + rivaroxaban	Rivaroxaban	45/31		57.7 ± 4.5		14	Drawing lots	1；5；6
Wang Xiaobo, 2019 [13]	42/42	Xueshuantong injection + urokinase injection	Urokinase injection	27/15	25/17	68.7 ± 5.5	68.3 ± 5.6	14	—	2；3；4
Xu Chunyu, 2019 [14]	45/45	Xueshuantong injection + urokinase injection + low molecular weight heparin	Urokinase injection + low molecular weight heparin	25/20	24/21	59.12 ± 6.34	58.49 ± 6.28	14	Random number table	5；6；8
Chen Kui, 2018 [15]	34/34	Xueshuantong injection + urokinase injection + low molecular weight heparin	Urokinase injection + low molecular weight heparin	19/15	18/16	53.96 ± 18.95	54.14 ± 19.02	14	Admission sequence	1; 5；6；7；8
Pan Lei, 2018 [16]	63/63	Xueshuantong injection + rivaroxaban	Rivaroxaban	32/31	33/30	65.09 ± 4.12	65.24 ± 4.27	14	Random number table	1；7；9
Zhang Yanwen, 2018 [17]	25/25	Xueshuantong injection + low molecular weight heparin	Low molecular weight heparin	14/11	15/10	67.83 ± 7.24	67.19 ± 6.25	14	—	1；7；8；9
Zhou Bo, 2015 [18]	44/43	Xueshuantong injection + low molecular weight heparin + warfarin	Low molecular weight heparin + warfarin	30/14	29/14	64.3 ± 5.2	64.8 ± 5.5	10	—	1；8
Zhou Yuhu, 2015 [19]	39/39	Xueshuantong injection + rivaroxaban	Rivaroxaban	21/18	20/19	66.52 ± 3.63	66.61 ± 3.72	14	—	1；5；6；7；8；9
Zhang Jianping, 2012 [20]	28/28	Xueshuantong injection + urokinase injection + low molecular weight heparin + aspirin	Urokinase injection + low molecular weight heparin + aspirin	18/10	15/13	57.25 ± 13.64	55.31 ± 14.26	14	Random number table	2；3；4；9

Note. ① Clinical efficiency. ② Patency rate of femoral vein. ③ Patency rate of the popliteal vein. ④ Patency rate of the posterior tibial vein. ⑤ Circumference difference of upper knee limb. ⑥ Circumference difference of lower knee limb. ⑦ APTT. ⑧ D-D. ⑨ Incidence of adverse events.